Editas Medicine to Present Groundbreaking LDL-Cholesterol-Lowering CRISPR Gene Editing Research at ESGCT Congress 2025

Editas Medicine to present CRISPR gene editing research at ESGCT Congress, highlighting LDL-cholesterol-lowering advancements.

Quiver AI Summary

Editas Medicine, Inc., a gene editing company, announced it will present at the European Society of Gene and Cell Therapy Congress in Seville, Spain, from October 7-10, 2025. The oral presentation, scheduled for October 9 at 5:00 p.m. CEST, will showcase their innovative CRISPR gene editing approach that lowers LDL cholesterol by upregulating LDLR in mice and non-human primates. Dr. Linda Burkly, the company's Executive Vice President and Chief Scientific Officer, will lead the presentation. Editas also plans to participate in investor conferences in October, including a fireside chat and a panel discussion on genome editing technologies. Presentation materials will be available on both the ESGCT and Editas websites.

Potential Positives

Editas Medicine will present significant findings on LDL-cholesterol-lowering CRISPR gene editing at a major European conference, enhancing its visibility in the scientific community.
The company’s participation in multiple investor conferences in October shows a commitment to engaging with investors and promoting its innovations.
The oral presentation by a high-level executive, Linda Burkly, Ph.D., underscores the expertise within the company and reinforces investor confidence in its leadership.
Editas Medicine's exclusive license agreements with prestigious institutions like the Broad Institute and Harvard University strengthen its position in the gene editing market.

Potential Negatives

Details about the specific outcomes or advancements being presented at the ESGCT Congress could indicate a lack of substantial progress or results, which may raise questions about the effectiveness of the company's research efforts.
The presentation primarily focuses on animal models (mice and non-human primates), which might suggest that human applications are still far from realization, potentially leading to investor concerns about timelines for product development.

FAQ

What is the focus of Editas Medicine?

Editas Medicine develops transformative gene editing medicines for serious diseases using CRISPR technology.

When is Editas Medicine's presentation at the ESGCT Congress?

The presentation is on October 9, 2025, at 5:00 p.m. CEST / 11:00 a.m. ET.

Who will present at the ESGCT Congress?

Linda Burkly, Ph.D, Executive Vice President and Chief Scientific Officer of Editas Medicine, will be the presenter.

Where can I find the presentation after the ESGCT Congress?

The presentation will be available in the “Posters & Presentations” section of Editas Medicine's website.

What other conferences will Editas Medicine participate in?

Editas Medicine will participate in the H.C. Wainwright Genetic Medicines Virtual Conference and the Chardan Genetic Medicines Conference in October.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$EDIT Insider Trading Activity

$EDIT insiders have traded $EDIT stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $EDIT stock by insiders over the last 6 months:

GILMORE NEIL O'NEILL (CEO) has made 0 purchases and 2 sales selling 20,784 shares for an estimated $40,712.
LINDA BURKLY (EVP, CHIEF SCIENTIFIC OFFICER) has made 0 purchases and 3 sales selling 6,557 shares for an estimated $15,851.
AMY PARISON (SVP, Chief Financial Officer) has made 0 purchases and 3 sales selling 1,583 shares for an estimated $3,709.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$EDIT Hedge Fund Activity

We have seen 75 institutional investors add shares of $EDIT stock to their portfolio, and 76 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,600,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $5,720,000
MILLENNIUM MANAGEMENT LLC added 1,590,955 shares (+557.3%) to their portfolio in Q2 2025, for an estimated $3,500,101
MORGAN STANLEY removed 1,238,238 shares (-46.6%) from their portfolio in Q2 2025, for an estimated $2,724,123
WOODLINE PARTNERS LP added 846,399 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,862,077
NUVEEN, LLC added 633,230 shares (+200.0%) to their portfolio in Q2 2025, for an estimated $1,393,106
UBS GROUP AG removed 586,015 shares (-48.2%) from their portfolio in Q2 2025, for an estimated $1,289,233
CITADEL ADVISORS LLC added 522,025 shares (+447.4%) to their portfolio in Q2 2025, for an estimated $1,148,455

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$EDIT Analyst Ratings

Wall Street analysts have issued reports on $EDIT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 08/15/2025
Baird issued a "Outperform" rating on 05/13/2025

To track analyst ratings and price targets for $EDIT, check out Quiver Quantitative's $EDIT forecast page.

$EDIT Price Targets

Multiple analysts have issued price targets for $EDIT recently. We have seen 4 analysts offer price targets for $EDIT in the last 6 months, with a median target of $4.5.

Here are some recent targets:

Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $5.0 on 09/05/2025
Yanan Zhu from Wells Fargo set a target price of $4.0 on 09/03/2025
Joel Beatty from Baird set a target price of $6.0 on 08/13/2025

Full Release

CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain.

European Society of Gene and Cell Therapy (ESGCT) Congress
Title: A transformative LDL-cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates
Session Date and Time: Thursday, October 9, 5:00 p.m. CEST / 11:00 a.m. ET
Session Title: 9A: Gene Editing II, Ex Vivo Applications
Room: Parallel A
Presenter: Linda Burkly, Ph.D, Executive Vice President and Chief Scientific Officer, Editas Medicine
Final Abstract Number: OR069

Abstracts are available to registrants on the ESGCT website . The oral presentation will also be posted to the “ Posters & Presentations ” section of the Company’s website at the time of the presentation and will remain accessible following the event.

In addition, management will participate in the following upcoming investor conferences in October:

H.C. Wainwright Genetic Medicines Virtual Conference
Format: Fireside Chat
Date: Tuesday, October 14, 7:00 a.m. ET
Location: Virtual

Chardan 9 ^th Annual Genetic Medicines Conference
Panel Discussion: Genome Editing: Next Wave Technologies
Date: Tuesday, October 21, 8:45 a.m. ET
Location: New York, NY

To access a live webcast of the presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com . An archived replay will be available for approximately 30 days following each event.

About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.